{"protocolSection":{"identificationModule":{"nctId":"NCT03940703","orgStudyIdInfo":{"id":"MS200095_0031"},"secondaryIdInfos":[{"id":"2019-001538-33","type":"EUDRACT_NUMBER"},{"id":"2024-512005-87-00","type":"CTIS"}],"organization":{"fullName":"EMD Serono","class":"INDUSTRY"},"briefTitle":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","officialTitle":"A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-09-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-05-11","type":"ACTUAL"},"completionDateStruct":{"date":"2026-05-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-05-06","studyFirstSubmitQcDate":"2019-05-06","studyFirstPostDateStruct":{"date":"2019-05-07","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-05-06","resultsFirstSubmitQcDate":"2024-05-06","resultsFirstPostDateStruct":{"date":"2024-06-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-28","lastUpdatePostDateStruct":{"date":"2025-12-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"EMD Serono Research & Development Institute, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Tepotinib","Osimertinib","Non-Small Cell Lung Cancer","INSIGHT 2","MET amplified"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":140,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tepotinib and Osimertinib","type":"EXPERIMENTAL","description":"Participants received a single oral dose of Tepotinib 500 milligrams (mg) followed by Omisertinib 80 mg once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.","interventionNames":["Drug: Tepotinib","Drug: Osimertinib"]},{"label":"Tepotinib Mono-therapy","type":"EXPERIMENTAL","description":"Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.","interventionNames":["Drug: Tepotinib"]}],"interventions":[{"type":"DRUG","name":"Tepotinib","description":"Participants were administered with Tepotinib orally once daily at a dose of 500 mg.","armGroupLabels":["Tepotinib Mono-therapy","Tepotinib and Osimertinib"]},{"type":"DRUG","name":"Osimertinib","description":"Participants received Osimertinib at a dose of 80 mg orally once daily.","armGroupLabels":["Tepotinib and Osimertinib"],"otherNames":["TagrissoÂ®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)","description":"DLTs are defined as any of the following toxicities and judged by the Investigator and/or the Sponsor to be not attributable to the disease or disease-related processes under investigation: Grade 4 neutropenia for more than 7 days; Grade greater than or equal to (\\>=) 3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding; Grade \\>= 3 nausea/vomiting and/or diarrhea that has not improved within 72 hours despite adequate and optimal treatment; Any other Grade \\>= 3 non-hematological AE, except alopecia or Grade 3 nauseas/vomiting and/or diarrhea that has improved within 72 hours with optimal treatment.","timeFrame":"Up to Day 21 of Cycle 1 (each Cycle is of 21 days)"},{"measure":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"}],"secondaryOutcomes":[{"measure":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Number of Participants With Clinically Significant Abnormalities in Laboratory Values Reported as Treatment Related TEAEs","description":"The laboratory measurements included hematology, biochemistry, coagulation and urinalysis. Number of participants with clinically significant abnormalities in laboratory values reported as treatment related TEAEs were reported. Clinical significance was decided by investigator.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Number of Participants With Markedly Abnormal Vital Sign Measurements","description":"Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR), respiratory rate (RR) body weight (BW) and body temperature (BT). Markedly abnormal value (MAV) criteria for vital signs: SBP and DBP: maximal on treatment (TR) increase or decrease greater than (\\>) 40 millimeter of mercury (mmHg); PR: maximal on TR increase or decrease \\>40 beats per minute (bpm); RR: maximal on TR increase or decrease \\>10 breaths per minute (breaths/minute), BW: maximum on TR increase or decrease \\>=10% and BT: maximal on TR increase greater than or equal to (\\>=)2 degree Celsius. Number of participants who met the MAV criteria for vital signs at least once post dose were reported.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score","description":"ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with shifts in score from baseline value vs worst post-baseline value (that is \\[i.e.\\] highest score).","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings","description":"Electrocardiograms (ECG) was obtained after the participant has been in a semi-supine position for at least 5 min. ECG parameters included heart rate, PQ/PR duration, QRS and QT duration, QT Interval. Clinical significance was determined by the investigator. Number of participants with clinically significant abnormalities in 12-lead ECG were reported.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by FISH","description":"Overall survival is defined as the time from first administration of study treatment to the date of death.","timeFrame":"Time from first administration of study treatment to the date of death, assessed approximately up to 42 months"},{"measure":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy ((Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Overall survival is defined as the time from first administration of study treatment to the date of death.","timeFrame":"Time from first administration of study treatment to the date of death, assessed approximately up to 42 months"},{"measure":"Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Investigator in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Monotherapy (Tepotinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Monotherapy (Tepotinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)"},{"measure":"Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Safety Follow-up (42 Months)","description":"The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.","timeFrame":"Baseline, safety follow-up (assessed up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status) at Safety Follow-up (42 Months)","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","timeFrame":"Baseline, safety follow-up (up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in Health-Related Quality of Life as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) at Safety Follow-up (42 Months)","description":"NSCLC-SAQ was a question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 5 domains: cough, pain, dyspnea, fatigue, and appetite. The NSCLC-SAQ score ranged from 0 to 20; High score indicated more severe NSCLC-related symptomatology. mains: cough, pain, dyspnea, fatigue, and appetite.","timeFrame":"Baseline, safety follow-up (up to 42 months)"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Maximum Observed Plasma Concentration (Cmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Cmax was obtained directly from the concentration versus time curve.","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Tmax was obtained directly from the concentration versus time curve.","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Apparent Total Body Clearance (CL/f) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]"},{"measure":"Combined Therapy (Tepotinib + Osimertinib): Apparent Volume Of Distribution (Vz/F) of of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf\\*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]"},{"measure":"Percentage of Participants With Resistant Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene or Other Pathways as Assessed in Circulating Tumor Deoxyribonucleic Acid (ctDNA)","description":"Percentage of participants with resistant mutations of the EGFR gene or other pathways as assessed in ctDNA were reported.","timeFrame":"From Day 1 of Cycle 3 up to end of treatment (14 days after last dose, approximately assessed up to 35.6 months) (each Cycle is for 21 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) histology (confirmed by either histology or cytology) with documented activating Epidermal Growth Factor Receptor (EGFR) mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a minimum life expectancy of 12 weeks\n* Acquired resistance on previous first-line osimertinib. Participants must meet both of the following 2 criteria:\n* Radiological documentation of disease progression on first-line osimertinib\n* Objective clinical benefit documented during previous osimertinib therapy, defined by either partial or complete radiological response, or durable stable disease (SD) (SD should last greater than (\\>) 6 months after initiation of osimertinib\n* Have received only first-line osimertinib as a prior line of therapy in the non curative advanced or metastatic NSCLC setting\n* MET amplification as determined by either FISH testing (central or local) on tumor tissue (TBx) or central blood-based next generation sequencing (LBx). Tumor and blood samples must be collected following progression on prior first-line osimertinib at Prescreening\n* Submission of tumor tissue and blood sample obtained after progression on first-line osimertinib, is mandatory for all patients for MET amplification testing\n* Submission of tumor tissue during Prescreening or Screening is mandatory for patients with tumor tissue tested by local FISH, to confirm MET amplification status. Central confirmation is not mandated prior to the start of study treatment\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Spinal cord compression or brain metastasis unless asymptomatic, stable or not requiring steroids for at least 2 weeks prior to start of study intervention\n* Any unresolved toxicity Grade 2 or more according to National cancer institute common terminology criteria for adverse events( NCI-CTCAE) version 5, from previous anticancer therapy with the exception of alopecia\n* Inadequate hematological, liver and renal function\n* Impaired cardiac function\n* History of interstitial lung disease(ILD) or interstitial pneumonitis including radiation pneumonitis that required steroid treatment\n* Hypertension uncontrolled by standard therapies (not stabilized to \\< 150/90 millimeter of mercury (mmHg)\n* Contraindication to the administration of osimertinib\n* Other protocol defined exclusion criteria could apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Responsible","affiliation":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Yuma Regional Medical Center","city":"Yuma","state":"Arizona","zip":"85364","country":"United States","geoPoint":{"lat":32.72532,"lon":-114.6244}},{"facility":"Compassionate Care Research Group Inc - Edinger Medical Group, Inc.","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Memorial Care","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Ventura County Hematology Oncology Specialists","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Innovative Clinical Research Institute","city":"Whittier","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"Eastern Connecticut Hematology & Oncology Associates","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Holy Cross","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Memorial Healthcare System","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Cancer Specialists of North Florida","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Ocala Oncology","city":"Ocala","state":"Florida","zip":"34474","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"University Cancer and Blood Center","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Hawaii Cancer Care","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"University of Chicago Medical Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Fort Wayne Medical Oncology and Hematology","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Community Health Network","city":"Indianapolis","state":"Indiana","zip":"46250","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Beacon Health","city":"South Bend","state":"Indiana","zip":"46601","country":"United States","geoPoint":{"lat":41.68338,"lon":-86.25001}},{"facility":"Norton Cancer Institute","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Pontchartrain","city":"Hammond","state":"Louisiana","zip":"70433","country":"United States","geoPoint":{"lat":30.50463,"lon":-90.46293}},{"facility":"Medstar Franklin Square Clinical Research Center","city":"Baltimore","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"The Center for Cancer & Blood Disorders - Maryland","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"Frederick Health- James M Stockman Cancer Institute","city":"Frederick","state":"Maryland","zip":"21702","country":"United States","geoPoint":{"lat":39.41427,"lon":-77.41054}},{"facility":"Boston Medical Center - Dept. Hematology/Oncology","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Southcoast Center for Cancer Care","city":"Fairhaven","state":"Massachusetts","zip":"02719","country":"United States","geoPoint":{"lat":41.6376,"lon":-70.90365}},{"facility":"Sparrow Hospital Herbert - Herman Cancer Center","city":"Lansing","state":"Michigan","zip":"48912","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"Central Care Cancer Center (CCCC)","city":"Bolivar","state":"Missouri","zip":"65613","country":"United States","geoPoint":{"lat":37.61448,"lon":-93.41047}},{"facility":"St. Louis Cancer Care, LLP","city":"Bridgeton","state":"Missouri","zip":"63044","country":"United States","geoPoint":{"lat":38.767,"lon":-90.41151}},{"facility":"Mosaic Life Care","city":"Saint Joseph","state":"Missouri","zip":"64507","country":"United States","geoPoint":{"lat":39.76861,"lon":-94.84663}},{"facility":"Comprehensive Cancer Centers of Nevada","city":"Las Vegas","state":"Nevada","zip":"89169","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"New Jersey Cancer Care and Blood Disorders","city":"Belleville","state":"New Jersey","zip":"07109","country":"United States","geoPoint":{"lat":40.79371,"lon":-74.15014}},{"facility":"Summit Medical Group","city":"Florham Park","state":"New Jersey","zip":"07932","country":"United States","geoPoint":{"lat":40.78788,"lon":-74.38821}},{"facility":"NYU Langone Clinical Cancer Center - NYU Langone Medical Center","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"NYU Langone Clinical Cancer Center - NYU Langone Medical Cente","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Weill Cornell Medical College - Gastroenterology","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Southeastern Medical Oncology Center","city":"Goldsboro","state":"North Carolina","zip":"27534","country":"United States","geoPoint":{"lat":35.38488,"lon":-77.99277}},{"facility":"University Hospitals Seidman","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"OhioHealth","city":"Columbus","state":"Ohio","zip":"43214","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Oklahoma Cancer Specialists and Research Institute","city":"Tulsa","state":"Oklahoma","zip":"74146","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Oregon Oncology Specialists","city":"Salem","state":"Oregon","zip":"97301","country":"United States","geoPoint":{"lat":44.9429,"lon":-123.0351}},{"facility":"Gettysburg Cancer Center","city":"Gettysburg","state":"Pennsylvania","zip":"17325","country":"United States","geoPoint":{"lat":39.83093,"lon":-77.2311}},{"facility":"Sanford Health","city":"Sioux Falls","state":"South Dakota","zip":"57104","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"Avera Cancer Institute","city":"Sioux Falls","state":"South Dakota","zip":"57108","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"Baptist Cancer Center","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Tennessee Oncology","city":"Nashville","state":"Tennessee","zip":"37201","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Mary Crowley Cancer Research","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Community Cancer Trials of Utah","city":"Ogden","state":"Utah","zip":"84405","country":"United States","geoPoint":{"lat":41.223,"lon":-111.97383}},{"facility":"Utah Cancer Specialists","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Hematology Oncology Associates of Fredericksburg","city":"Fredericksburg","state":"Virginia","zip":"22408","country":"United States","geoPoint":{"lat":38.30318,"lon":-77.46054}},{"facility":"Northwest Medical Specialties","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"UZ Antwerpen - Department of Oncology","city":"Edegem","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"UZ Leuven","city":"Gasthuisberg","country":"Belgium"},{"facility":"AZ Delta","city":"Roeselare","country":"Belgium","geoPoint":{"lat":50.94653,"lon":3.12269}},{"facility":"Beijing Hospital","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking Union Medical College Hospital","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking University Cancer Hospital","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Jilin Cancer Hospital - Oncology","city":"Changchun","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"The First Hospital of Jilin University","city":"Changchun","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Hunan Cancer Hospital","city":"Changsha","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"West China Hospital, Sichuan University","city":"Chengdu","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Fujian Cancer Hospital","city":"Fuzhou","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"Guangdong General Hospital","city":"Guangzhou","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The First Affiliated Hospital, Zhejiang University","city":"Hangzhou","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Affiliated Tumor Hospital of Harbin Medical University","city":"Harbin","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Anhui Chest Hospital","city":"Hefei","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Linyi Tumor Hospital","city":"Linyi","country":"China","geoPoint":{"lat":35.06306,"lon":118.34278}},{"facility":"Jiangsu Province Hospital","city":"Nanjing","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Shanghai Cancer Hospital, Fudan University","city":"Shanghai","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai Chest Hospital","city":"Shanghai","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Liaoning Cancer Hospital & Institute","city":"Shenyang","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"The Affiliated Cancer Hospital of Xinjiang Medical university","city":"ÃrÃ¼mqi","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Hubei Cancer Hospital","city":"Wuhan","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Union Hospital Tongji Medical College Huazhong University of Science and Technology","city":"Wuhan","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Centre Francois Baclesse - Service d'Oncologie Medicale","city":"Caen","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Centre Hospitalier Intercommunal de CrÃ©teil - Service de Pneumologie","city":"CrÃ©teil","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"CHU Limoges - HÃ´pital Dupuytren - Unite d'Oncologie Thoracique et CutanÃ©e","city":"Limoges","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Centre LÃ©on BÃ©rard","city":"Lyon","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Hopital Albert Calmette - CHU Lille - service de pneumologie et immuno allergologie","city":"Nord","country":"France"},{"facility":"Hopital Tenon - service pneumologie","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hospital Cochin Service, Service de Pneumologie et Mucoviscidose","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Groupe Hospitalier Sud - HÃ´pital Haut-LÃ©vÃªque - Maison du Ha","city":"Pessac","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"CHU de Toulouse - HÃ´pital Larrey - Service de Pneumologie et Oncologie Pneumologique","city":"Toulouse","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Universitaetsklinikum Koeln - Innere Medizin I, Onkologie, Haematologie","city":"Cologne","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Universitaetsklinikum Carl Gustav Carus TU Dresden","city":"Dresden","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Asklepios Fachkliniken Muenchen-Gauting - Abteilung internistische Onkologie","city":"Gauting","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen","city":"Giessen","country":"Germany","geoPoint":{"lat":50.58727,"lon":8.67554}},{"facility":"Universitaetsmedizin Goettingen","city":"GÃ¶ttingen","country":"Germany","geoPoint":{"lat":51.53443,"lon":9.93228}},{"facility":"Evangelisches Krankenhaus Hamm gGmbH","city":"Hamm","country":"Germany","geoPoint":{"lat":51.68033,"lon":7.82089}},{"facility":"Evangelisches Krankenhaus Hamm GmbH","city":"Hamm","country":"Germany","geoPoint":{"lat":51.68033,"lon":7.82089}},{"facility":"Thoraxklinik-Heidelberg gGmbH","city":"Heidelberg","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Staedtisches Krankenhaus Kiel","city":"Kiel","country":"Germany","geoPoint":{"lat":54.32133,"lon":10.13489}},{"facility":"POIS Leipzig GbR","city":"Leipzig","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Universitaetsklinikum Schleswig-Holstein - Campus Luebeck","city":"LÃ¼beck","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Pius-Hospital Oldenburg - Klinik f. Haematologie und Onkologie","city":"Oldenburg","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"MissionsÃ¤rztliche Klinik","city":"WÃ¼rzburg","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Queen Elizabeth Hospital - Department of Medicine","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"The University of Hong Kong","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"The Chinese University of Hong Kong - Emergency Medicine","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica","city":"Lazio","country":"Italy"},{"facility":"IEO Istituto Europeo di Oncologia","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo) - U.O Oncologia Medica","city":"Monza","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Ospedale Monaldi","city":"Napoli","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"IOV - Istituto Oncologico Veneto IRCCS - Oncologia Medica 2","city":"Padua","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"AO Ospedali Riuniti Cervello - Presidio Villa Sofia - U.O.S. di Neuroimmunologia","city":"Palermo","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Azienda Ospedaliero Universitaria Pisana - U.O. Pneumologia II","city":"Pisa","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Istituto Nazionale Tumori Regina Elena IRCCS - S.C. Oncologia Medica B","city":"Roma","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Istituto Clinico Humanitas","city":"Rozzano","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Azienda Socio Sanitaria Territoriale Sette Laghi (Presidio Ospedale di Circolo e Fondazione Macchi) - Oncologia Medica","city":"Varese","country":"Italy","geoPoint":{"lat":45.82058,"lon":8.82511}},{"facility":"Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) - U.O.C. Oncologia","city":"Verona","country":"Italy","geoPoint":{"lat":45.43854,"lon":10.9938}},{"facility":"Hamamatsu University School of Medicine, University Hospital - Dept of Respiratory Medicine","city":"Hamamatsu","country":"Japan","geoPoint":{"lat":34.7,"lon":137.73333}},{"facility":"Saitama Cancer Center","city":"Kitaadachi-gun","country":"Japan"},{"facility":"Kurume University Hospital","city":"Kurume-shi","country":"Japan"},{"facility":"Nagoya University Hospital - Dept of Respiratory Medicine","city":"Nagoya","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Niigata Cancer Center Hospital - Dept of Internal Medicine","city":"Niigata","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Hyogo College of Medicine Hospital - Dept of Respiratory Medicine","city":"Nishinomiya-shi","country":"Japan"},{"facility":"Okayama University Hospital - Dept of Respiratory Medicine/Allergy","city":"Okayama","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka City General Hospital","city":"Osaka","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kindai University Hospital","city":"Osakasayama-shi","country":"Japan"},{"facility":"NHO Yamaguchi - Ube Medical Center","city":"Ube-shi","country":"Japan"},{"facility":"Kanagawa Cancer Center - Dept of Respiratory Medicine","city":"Yokohama","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Pantai Hospital Kuala Lumpur","city":"Kuala Lumpur","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"University Malaya Medical Centre","city":"Kuala Lumpur","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Beacon International Specialist Centre Sdn Bhd","city":"Kuala Selangor","country":"Malaysia","geoPoint":{"lat":3.35,"lon":101.25}},{"facility":"Hospital Tengku Ampuan Afzan","city":"Kuantan","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"facility":"Hospital Umum Sarawak","city":"Kuching","country":"Malaysia","geoPoint":{"lat":1.55,"lon":110.33333}},{"facility":"Sunway Medical Centre","city":"Petaling Jaya, Selangor","country":"Malaysia"},{"facility":"Hospital Pulau Pinang - Clinic Respiratory","city":"Pulau Pinang","country":"Malaysia","geoPoint":{"lat":3.55,"lon":102.56667}},{"facility":"The Netherlands Cancer Institute","city":"Amsterdam","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Universitair Medisch Centrum Groningen - Department of Internal Medicine","city":"Groningen","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Maastricht University Medical Center - Dept of Medical Oncology","city":"Maastricht","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"SBHI \"Krasnoyarsk Regional Oncology Dispensary n.a. A.I. Kryzhanovsky\"","city":"Krasnoyarsk","country":"Russia","geoPoint":{"lat":56.03742,"lon":92.93136}},{"facility":"\"VitaMed\" LLC","city":"Moscow","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"LLC \"Tonus\"","city":"Nizniy Novgorod","country":"Russia"},{"facility":"BHI of Omsk region \"Clinical Oncology Dispensary\"","city":"Omsk","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"LLC \"ClinicaUZI4D\"","city":"Pyatigorsk","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"FBI \"Scientific Research Institute of Oncology n. a. N. N. Petrov\"","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Pavlov First Saint Petersburg State Medical University - Research Institute of Pulmunology","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Icon Cancer Centre","city":"Connexion","country":"Singapore"},{"facility":"National Cancer Centre - Medical Oncology Pharmacy","city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Tan Tock Seng Hospital - CTRU/OCS, Research","city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Center","city":"Goyang-si","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Chonnam National University Hwasun Hospital","city":"Hwasun-gun","country":"South Korea"},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Asan Medical Center","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Anam Hospital","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Seoul National University Hospital","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea, Seoul St. Mary's Hospital","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan University Hospital","city":"Ulsan","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"ICO Badalona - Hospital Germans Trias i Pujol - Servicio de Oncologia Medica","city":"Badalona","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hospital del Mar - Servicio de Oncologia","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Dexeus - Servicio de Oncologia Medica","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron - Dept of Oncology","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"ICO lÂ´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia","city":"L'Hospitalet de Llobregat","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Hospital Universitario Materno-Infantil de Canarias - Servicio de Oncologia","city":"Las Palmas de Gran Canaria","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario de Malaga","city":"MÃ¡laga","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitari Son Espases - Servicio de Oncologia Medica","city":"Palma","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Universitario Quiron Madrid - Unidad Integral de Oncologia","city":"Pozuelo de AlarcÃ³n","country":"Spain","geoPoint":{"lat":40.43293,"lon":-3.81338}},{"facility":"Hospital Universitario Virgen Macarena - Servicio de Oncologia","city":"Seville","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Kaohsiung Chang Gung Memorial Hospital","city":"Kaohsiung City","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Chi Mei Medical Center, Liou Ying","city":"Tainan","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"National Taiwan University Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Tri-Service General Hospital","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Siriraj Hospital","city":"Bangkoknoi","country":"Thailand"},{"facility":"Songklanagarind Hospital","city":"Hat Yai","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Maharaj Nakorn Chiang Mai Hospital","city":"Muang","country":"Thailand"},{"facility":"King Chulalongkorn Memorial Hospital","city":"Pathumwan","country":"Thailand"},{"facility":"Bach Mai Hospital","city":"Hanoi","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"K Hospital","city":"Hanoi","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"National Lungs Hospital","city":"Hanoi","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Cho Ray Hospital","city":"Ho Chi Minh City","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"HCMC Oncology Hospital","city":"Ho Chi Minh City","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"Pham Ngoc Thach Hospital","city":"Ho Chi Minh City","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}}]},"referencesModule":{"references":[{"pmid":"34918545","type":"BACKGROUND","citation":"F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol. 2022 Mar;18(9):1039-1054. doi: 10.2217/fon-2021-1406. Epub 2021 Dec 17."},{"pmid":"39089305","type":"DERIVED","citation":"Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5."},{"pmid":"36999526","type":"DERIVED","citation":"Hallick J, Baird AM, Falchook G, Le X, Hong D, Viteri S, Raskin J, Reinmuth N, Vlassak S, Militaru M, Paik PK. Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping. Future Oncol. 2023 Mar;19(10):683-696. doi: 10.2217/fon-2022-1035. Epub 2023 Mar 31."}],"seeAlsoLinks":[{"label":"Trial Awareness and Transparency website","url":"https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200095_0031"},{"label":"US Medical Information website, Medical Resources","url":"https://medical.emdserono.com/en_US/home.html"},{"label":"Targeting MET Clinical Trial Program","url":"https://www.clinicaltrials.targeting-met.com/en"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union","accessCriteria":"Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.","url":"http://bit.ly/IPD21"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Tepotinib and Osimertinib","description":"Participants received a single oral dose of Tepotinib 500 milligrams (mg) followed by Omisertinib 80 mg once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"FG001","title":"Tepotinib Mono-therapy","description":"Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Full Analysis Set (FAS)","comment":"FAS included all participants who were administered any dose of any study treatment.","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Safety (SAF) Analysis Set","comment":"SAF analysis set included all participants who were administered any dose of any study treatment.","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Modified Full Analysis Set (mFAS)","comment":"mFAS: All FAS/SAF participants who started study treatment on or before the 08 July 2022 (that is \\[i.e.\\] date of completion of global enrollment), tested positive for MET amplification by either central test on tumor tissue or liquid biopsy or both, and progressed on first-line osimertinib as the only prior line of therapy in the noncurative advanced or metastatic NSCLC setting. T+ participants also belong to the Primary Analysis Set for Efficacy.","achievements":[{"groupId":"FG000","numSubjects":"105"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Safety run-in Analysis Set (SRIAS)","comment":"SRIAS included all FAS/SAF participants treated during the safety run-in period who received at least 75 percent (% )of the tepotinib and osimertinib planned dose and completed the Dose-Limiting Toxicity (DLT) period (3 weeks after start of study treatment), or who experienced a DLT during the DLT period regardless of the received amount of each study treatment component.","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Pharmacokinetic (PK) Analysis Set","comment":"PK analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration.","achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"97"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Still under treatment","reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","groups":[{"id":"BG000","title":"Tepotinib and Osimertinib","description":"Participants received a single oral dose of Tepotinib 500 milligrams (mg) followed by Omisertinib 80 mg once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"BG001","title":"Tepotinib Mono-therapy","description":"Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"140"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59","spread":"10.8"},{"groupId":"BG001","value":"61","spread":"9.7"},{"groupId":"BG002","value":"60","spread":"10.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"83"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"57"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity-Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]},{"title":"Ethnicity-Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"136"}]}]},{"title":"Ethnicity-Unknown or Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Race-Asian","categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"85"}]}]},{"title":"Race-Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Race-Not Collected At This Site","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]},{"title":"Race-Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Race-White","categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"47"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)","description":"DLTs are defined as any of the following toxicities and judged by the Investigator and/or the Sponsor to be not attributable to the disease or disease-related processes under investigation: Grade 4 neutropenia for more than 7 days; Grade greater than or equal to (\\>=) 3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding; Grade \\>= 3 nausea/vomiting and/or diarrhea that has not improved within 72 hours despite adequate and optimal treatment; Any other Grade \\>= 3 non-hematological AE, except alopecia or Grade 3 nauseas/vomiting and/or diarrhea that has improved within 72 hours with optimal treatment.","populationDescription":"Safety run-in analysis set (SRIAS): all FAS/SAF participants treated during the safety run-in period who received at least 75% of the tepotinib and osimertinib planned dose and completed the DLT period (3 weeks after start of study treatment), or who experienced a DLT during the DLT period regardless of the received amount of each study treatment component.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 21 of Cycle 1 (each Cycle is of 21 days)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"PRIMARY","title":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic Epidermal Growth Factor Receptor mutation positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC) and Mesenchymal-Epithelial Transition factor (MET) amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"39.7","upperLimit":"60.3"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all modified Full Analysis Set (mFAS) participants with advanced or metastatic Epidermal Growth Factor Receptor mutation positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC) and Mesenchymal-Epithelial Transition factor (MET) amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","lowerLimit":"36.0","upperLimit":"72.7"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention.","populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"12"}]}]},{"title":"Treatment-related TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Abnormalities in Laboratory Values Reported as Treatment Related TEAEs","description":"The laboratory measurements included hematology, biochemistry, coagulation and urinalysis. Number of participants with clinically significant abnormalities in laboratory values reported as treatment related TEAEs were reported. Clinical significance was decided by investigator.","populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Anemia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Febrile neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Leukopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Myelosuppression","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymphocyte count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Platelet count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"White blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alanine aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alkaline phosphatase increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lipase increased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypoalbuminemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Urinary tract infection","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Activated partial thromboplastin time","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Prothrombin international normalized ratio","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Vital Sign Measurements","description":"Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR), respiratory rate (RR) body weight (BW) and body temperature (BT). Markedly abnormal value (MAV) criteria for vital signs: SBP and DBP: maximal on treatment (TR) increase or decrease greater than (\\>) 40 millimeter of mercury (mmHg); PR: maximal on TR increase or decrease \\>40 beats per minute (bpm); RR: maximal on TR increase or decrease \\>10 breaths per minute (breaths/minute), BW: maximum on TR increase or decrease \\>=10% and BT: maximal on TR increase greater than or equal to (\\>=)2 degree Celsius. Number of participants who met the MAV criteria for vital signs at least once post dose were reported.","populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"SBP: maximum on TR increase of >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"SBP: maximum on TR decrease of >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}]},{"title":"DBP: maximum on TR increase of >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"DBP: maximum on TR decrease of >40 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"RR: maximum on TR increase of >10 beats/min","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"RR: maximum on TR decrease of >10 beats/min","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"PR: maximum on TR increase of > 40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"PR: maximum on TR decrease of >40 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"BW: maximum on TR increase of >=10%","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"1"}]}]},{"title":"BW: maximum on TR decrease of >=10%","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"}]}]},{"title":"BT: maximal on TR increase >=2 degree Celsius","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score","description":"ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with shifts in score from baseline value vs worst post-baseline value (that is \\[i.e.\\] highest score).","populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Maximum Baseline score 0, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"1"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 0, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"5"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"1"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Maximum Baseline score 1, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"4"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 0, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 0","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"2"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 1","categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"5"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 3","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Minimum Baseline score 1, worst post-baseline score missing","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings","description":"Electrocardiograms (ECG) was obtained after the participant has been in a semi-supine position for at least 5 min. ECG parameters included heart rate, PQ/PR duration, QRS and QT duration, QT Interval. Clinical significance was determined by the investigator. Number of participants with clinically significant abnormalities in 12-lead ECG were reported.","populationDescription":"Safety (SAF) analysis set included all participants who were administered any dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","lowerLimit":"34.8","upperLimit":"55.3"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"6.1","upperLimit":"NA","comment":"Due to small number of events, upper limit of 95% Confidence Interval from Kaplan-Meier survival curves could not be derived."}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"7.1","upperLimit":"NA","comment":"Due to small number of events, upper limit of 95% Confidence Interval from Kaplan-Meier survival curves could not be derived."}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","lowerLimit":"52.9","upperLimit":"72.8"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","lowerLimit":"54.0","upperLimit":"73.7"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.2","upperLimit":"8.1"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"4.2","upperLimit":"8.5"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by FISH","description":"Overall survival is defined as the time from first administration of study treatment to the date of death.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of death, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"11.1","upperLimit":"NA","comment":"Due to small number of events, upper limit of 95% confidence interval from Kaplan-Meier survival curves could not derive."}]}]}]},{"type":"SECONDARY","title":"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","lowerLimit":"30.2","upperLimit":"66.9"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"2.9","upperLimit":"15.4"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"2.9","upperLimit":"9.6"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","lowerLimit":"45.4","upperLimit":"80.8"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","lowerLimit":"48.6","upperLimit":"83.3"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"2.7","upperLimit":"7.2"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy ((Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.2","upperLimit":"7.0"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing","description":"Overall survival is defined as the time from first administration of study treatment to the date of death.","populationDescription":"The secondary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by liquid biopsy (LBx) test (L+).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of death, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","lowerLimit":"9.6","upperLimit":"NA","comment":"Due to small number of events, upper limit of 95% confidence interval from Kaplan-Meier survival curves could not derive."}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Investigator in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)","description":"Objective response was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Confirmed CR was defined as the disappearance of all evidence of target and non-target lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events, therefore 95% Confidence Interval could not be calculated."}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"DOR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response \\[CR\\] or Partial Response \\[PR\\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events, therefore 95% Confidence Interval could not be calculated."}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"Disease control rate is defined as the percentage of participants with objective resposne (complete resposne \\[CR\\] or partial resposne \\[PR\\] or stable disease \\[SD\\]). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.4","upperLimit":"4.4"}]}]}]},{"type":"SECONDARY","title":"Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH","description":"PFS was defined as the time is defined as the time from first administration of study treatment to the date of the first documentation of PD or death due to any cause within 126 days of the last tumor assessment, whichever occurs first. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from first administration of study treatment to the date of the first documentation of PD or death due to any cause, assessed approximately up to 42 months","groups":[{"id":"OG000","title":"Tepotinib Monotherapy","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.4","upperLimit":"4.4"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Safety Follow-up (42 Months)","description":"The EQ-5D-5L questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L profile defines health in terms of mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has five levels: 1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, safety follow-up (assessed up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11","spread":"21.7"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status) at Safety Follow-up (42 Months)","description":"EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, safety follow-up (up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"25.17"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in Health-Related Quality of Life as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) at Safety Follow-up (42 Months)","description":"NSCLC-SAQ was a question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 5 domains: cough, pain, dyspnea, fatigue, and appetite. The NSCLC-SAQ score ranged from 0 to 20; High score indicated more severe NSCLC-related symptomatology. mains: cough, pain, dyspnea, fatigue, and appetite.","populationDescription":"The primary analysis set for efficacy included all mFAS participants with advanced or metastatic EGFRm+ NSCLC and MET amplification, determined centrally by FISH (central TBx FISH testing \\[T+\\]). Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, safety follow-up (up to 42 months)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"4.26"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.","populationDescription":"Pharmacokinetic analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"number analyzed\" signifies those participants who were evaluable at specified timepoints for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"title":"Tepotinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11600","spread":"40.8"}]}]},{"title":"Tepotinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26900","spread":"47.1"}]}]},{"title":"MSC2571109A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2240","spread":"40.0"}]}]},{"title":"MSC2571109A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5160","spread":"50.3"}]}]},{"title":"MSC2571107A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"497","spread":"292.6"}]}]},{"title":"MSC2571107A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1180","spread":"624.7"}]}]},{"title":"Osimertinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9090","spread":"168.9"}]}]},{"title":"Osimertinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8710","spread":"41.3"}]}]},{"title":"AZD5104: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"808","spread":"424.6"}]}]},{"title":"AZD5104: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1010","spread":"54.6"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Maximum Observed Plasma Concentration (Cmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Cmax was obtained directly from the concentration versus time curve.","populationDescription":"PK analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"number analyzed\" signifies those participants who were evaluable at specified timepoints for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"title":"Tepotinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"660","spread":"38.7"}]}]},{"title":"Tepotinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1220","spread":"45.1"}]}]},{"title":"MSC2571109A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":"41.1"}]}]},{"title":"MSC2571109A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":"45.0"}]}]},{"title":"MSC2571107A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":"26.57"}]}]},{"title":"MSC2571107A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":"27.19"}]}]},{"title":"Osimertinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"540","spread":"144.6"}]}]},{"title":"Osimertinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"468","spread":"51.2"}]}]},{"title":"AZD5104: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":"421.2"}]}]},{"title":"AZD5104: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":"63.8"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Tmax was obtained directly from the concentration versus time curve.","populationDescription":"PK analysis set included all FAS/SAF participants who have no important events affecting PK and provide at least one measurable post-dose concentration. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"number analyzed\" signifies those participants who were evaluable at specified timepoints for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"title":"Tepotinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.97","lowerLimit":"6.00","upperLimit":"24.00"}]}]},{"title":"Tepotinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","lowerLimit":"0.50","upperLimit":"24.00"}]}]},{"title":"MSC2571109A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.00","lowerLimit":"12.00","upperLimit":"24.00"}]}]},{"title":"MSC2571109A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","lowerLimit":"0.00","upperLimit":"24.77"}]}]},{"title":"MSC2571107A: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.00","lowerLimit":"12.00","upperLimit":"24.00"}]}]},{"title":"MSC2571107A: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.00","lowerLimit":"0.00","upperLimit":"24.77"}]}]},{"title":"Osimertinib: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","lowerLimit":"2.00","upperLimit":"24.00"}]}]},{"title":"Osimertinib: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"3.00","upperLimit":"24.77"}]}]},{"title":"AZD5104: Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.00","lowerLimit":"1.50","upperLimit":"24.00"}]}]},{"title":"AZD5104: Cycle 1 Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","lowerLimit":"0.00","upperLimit":"24.77"}]}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Apparent Total Body Clearance (CL/f) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.","populationDescription":"As per changes in planned analysis, the PK parameter (CL/f) was not assessed.","reportingStatus":"POSTED","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Combined Therapy (Tepotinib + Osimertinib): Apparent Volume Of Distribution (Vz/F) of of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104","description":"Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf\\*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.","populationDescription":"As per changes in planned analysis, the PK parameter (Vz/f) was not assessed.","reportingStatus":"POSTED","timeFrame":"Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after tepotinib and Osimertinib administration at Day 1 of Cycle 1 and Day 15 of Cycle 1 (each Cycle is of 21 days) ]","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Resistant Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene or Other Pathways as Assessed in Circulating Tumor Deoxyribonucleic Acid (ctDNA)","description":"Percentage of participants with resistant mutations of the EGFR gene or other pathways as assessed in ctDNA were reported.","populationDescription":"As per changes in planned analysis, the data for mutation status in EGFR and other pathways in ctDNA at baseline and progression were not collected with the assay used to screen for MET amplification in ctDNA.","reportingStatus":"POSTED","timeFrame":"From Day 1 of Cycle 3 up to end of treatment (14 days after last dose, approximately assessed up to 35.6 months) (each Cycle is for 21 days)","groups":[{"id":"OG000","title":"Tepotinib + Osimertinib","description":"Participants received 500 milligrams (mg) of tepotinib orally once daily in combination with Osimertinib at a dose of 80 mg orally once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."},{"id":"OG001","title":"Tepotinib Mono-therapy","description":"Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)","eventGroups":[{"id":"EG000","title":"Tepotinib and Osimertinib","description":"Participants received a single oral dose of Tepotinib 500 milligrams (mg) followed by Omisertinib 80 mg once daily until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.","deathsNumAffected":59,"deathsNumAtRisk":128,"seriousNumAffected":49,"seriousNumAtRisk":128,"otherNumAffected":123,"otherNumAtRisk":128},{"id":"EG001","title":"Tepotinib Mono-therapy","description":"Participants received a single oral dose of Tepotinib 500 mg until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.","deathsNumAffected":7,"deathsNumAtRisk":12,"seriousNumAffected":2,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Carbuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Cerebral venous sinus thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lung consolidation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":26,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Ear congestion","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Aerophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":91,"numAffected":69,"numAtRisk":128},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":12}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":36,"numAtRisk":128},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":12}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":25,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":79,"numAffected":60,"numAtRisk":128},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":12}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":20,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Laryngopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":29,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":128},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":12}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":15,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":16,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":12}]},{"term":"Heart rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":18,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Urine bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Urine ketone body present","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":7,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":30,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":35,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":19,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":12,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Joint hyperextension","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Mobility decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":12}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Vasomotor rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Vocal cord fixation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":128},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Nail dystrophy","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Onychomadesis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":128},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":128},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Communication Center","organization":"Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany","email":"service@emdgroup.com","phone":"+49-6151-72-5200"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-05-04","uploadDate":"2024-05-06T10:37","filename":"Prot_000.pdf","size":2874564},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-04-04","uploadDate":"2024-05-06T10:37","filename":"SAP_001.pdf","size":1212247}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000707607","term":"tepotinib"},{"id":"C000596361","term":"osimertinib"}]}},"hasResults":true}